To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

A Phase 2a Trial Investig… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia

Journal article
Authors P. Svenningsson
P. Odin
N. Dizdar
A. Johansson
S. Grigoriou
P. Tsitsi
K. Wictorin
Filip Bergquist
D. Nyholm
J. Rinne
F. Hansson
C. Sonesson
J. Tedroff
Published in Movement Disorders
Volume 35
Issue 6
Pages 1046-1054
ISSN 0885-3185
Publication year 2020
Published at Institute of Neuroscience and Physiology, Department of Pharmacology
Pages 1046-1054
Language en
Links dx.doi.org/10.1002/mds.28020
Keywords apathy, axial symptom, cognition, fall, movement disorder, cognitive impairment, postural instability, multicenter, deficits, Neurosciences & Neurology
Subject categories Neurosciences

Abstract

Background IRL752 is a novel small-molecule compound that acts to regioselectively enhance norepinephrine, dopamine, and acetylcholine neurotransmission in the cerebral cortex. Objective The primary objective of the trial was to investigate the safety and tolerability of IRL752 in patients with Parkinson's disease and dementia. Methods Patients with Parkinson's disease and dementia were randomized to IRL752 or placebo treatment (3:1 ratio) for 28 days. The study drug was given as an adjunct treatment to the patients' regular stable antiparkinsonian medication. Dosing was individually titrated for 14 days after which the dose was kept stable for an additional 14 days. Results A total of 32 patients were randomized to treatment, and 29 patients completed the 4-week treatment. Adverse events were generally mild and transient and were mostly reported during the dose titration phase. There were 2 serious adverse events, and none of them were related to the experimental treatment. The average dose achieved in the stable dose phase was 600 mg daily, yielding a 2-hour postdose plasma concentration of about 4 mu M on day 28. Exploratory assessment of secondary outcomes indicated efficacy for symptoms and signs known to be poorly responsive to levodopa. Conclusions IRL752 appears to be safe and well tolerated for a 4-week treatment in patients with Parkinson's disease and dementia. (c) 2020 International Parkinson and Movement Disorder Society

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?